8-K: Waters Completes BD Biosciences & Diagnostics Merger

Waters Corporation finalized its acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business, creating a combined entity with significant debt and lower pro forma earnings.

Summary

• Waters Corporation (Waters) and Becton, Dickinson and Company (BD) completed the spin-off of BD's Biosciences and Diagnostic Solutions business (BDS Business) and its merger with Waters on February 9, 2026.
• The transaction was structured as a Reverse Morris Trust, intended to be tax-free for U.S. federal income tax purposes.
• Prior to the merger, SpinCo (the entity holding the BDS Business) made a $4.0 billion cash payment to BD, funded by $4.0 billion in unsecured term loans (SpinCo Financing).
• Waters issued 38,541,852 shares of its common stock to former BD shareholders, resulting in them owning approximately 39.2% of the combined Waters, while pre-merger Waters shareholders own approximately 60.8%.
• The unaudited pro forma combined financial information for the year ended December 31, 2025, shows total net sales of $6,392,985 thousand and net income of $61,891 thousand, with pro forma basic and diluted EPS of $0.63.
• The BDS Business's historical performance for the three months ended December 31, 2025, showed an 8.3% decrease in total net sales to $766 million and a 37.2% decrease in net income to $49 million compared to the prior-year period.
• Certain assets and liabilities of the BDS Business (Deferred Close Businesses) could not be legally transferred at closing due to regulatory and legal requirements in foreign jurisdictions, with Waters recording a $316,582 thousand prepaid deposit asset for these.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a complex transaction with significant strategic potential but also substantial financial headwinds, including a large debt burden and recent revenue declines in the acquired business, leading to a materially lower pro forma net income and EPS for the combined entity.

Positives

• The transaction was structured as a Reverse Morris Trust, providing a tax-efficient method for separating the BDS Business from BD.
• The BDS Business shows continued growth in specific platforms such as MAX IVD, COR, and the recently launched FACSDiscover A8 Cell Analyzer.
• Productivity initiatives and continuous improvement projects have led to lower manufacturing costs and improved operating margins in the Diagnostic Solutions segment of the BDS Business.
• The BDS Business's effective income tax rate for the three months ended December 31, 2025, reflected a more favorable net impact from discrete items compared with the prior-year period.

Negatives

• The BDS Business experienced an 8.3% decline in total net sales for the three months ended December 31, 2025, compared to the prior-year period, reaching $766 million.
• Net income for the BDS Business decreased by 37.2% to $49 million for the three months ended December 31, 2025, compared to the prior-year period.
• Operating income for the BDS Business declined by 62.8% to $35 million for the three months ended December 31, 2025, compared to the prior-year period.
• The pro forma combined net income for the year ended December 31, 2025, is $61,891 thousand, a significant decrease from Waters' historical net income of $642,629 thousand.
• Pro forma basic and diluted earnings per share are $0.63, substantially lower than Waters' historical basic EPS of $10.80 and diluted EPS of $10.76.
• The BDS Business faced softer research instrument demand due to funding constraints and market dynamics, as well as regulatory constraints impacting sales to China.
• Lower sales of point-of-care products and BACTEC blood culture products contributed to revenue declines in the Diagnostic Solutions segment.
• Increased costs due to tariffs and higher labor costs unfavorably impacted gross profit margins for the BDS Business.

Risks

• There is no assurance regarding if or when the Permanent SpinCo Financing will be consummated or the exact terms and interest rate of such financing.
• The pro forma purchase price allocation is based on preliminary estimates and is subject to change, with final valuations potentially differing materially and affecting goodwill, intangible assets, and depreciation/amortization expense.
• Waters management is still performing a detailed review of the BDS Business's accounting policies and may identify additional differences that could materially impact the pro forma financial information.
• The legal transfer of certain assets and liabilities of the BDS Business (Deferred Close Businesses) was delayed at closing due to regulatory, legal, and other compliance requirements in foreign jurisdictions.
• The BDS Business is involved in an intellectual property licensing agreement dispute regarding asserted underpaid royalties.
• The BDS Business is subject to Italy's medical device payback legislation, which could result in additional liabilities beyond the currently accrued $17 million.
• The combined company is exposed to foreign currency risk stemming from its international operations.

Future Outlook

The SpinCo Financing of $4.0 billion is expected to be replaced by long-term Permanent SpinCo Financing, potentially through the issuance of senior unsecured notes. Waters and BD will use reasonable best efforts to transfer the Deferred Close Businesses as promptly as reasonably practicable. Waters expects to recognize the majority of revenue from existing service contracts and pending equipment installations over the next three years, and revenue from minimum purchase commitments over customer relationship periods.

Management Comments

• Waters management believes that the assumptions included herein provide a reasonable basis for presenting the significant effects of the Transactions as contemplated, and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information.
• Waters management is performing a detailed review of the BDS Business's accounting policies and may identify additional differences, which could have a material impact on the unaudited pro forma condensed combined financial information.
• Management has evaluated subsequent events through February 27, 2026, the date the condensed combined financial statements were available to be issued, and did not identify any subsequent events that would have required adjustment or disclosure in the combined financial statements.

Industry Context

StockSavvy.ai notes that the acquisition of BD's Biosciences and Diagnostic Solutions business by Waters Corporation represents a significant consolidation in the life sciences and diagnostics sector. The strategic rationale for a Reverse Morris Trust transaction often centers on tax efficiency and the creation of a more focused entity. The BDS Business's performance, particularly the decline in research instrument demand and point-of-care products, suggests a challenging market environment, while growth in platforms like MAX IVD and COR indicates specific areas of strength. The integration of a business with declining revenue and significant debt will require careful management to realize the anticipated synergies and justify the substantial goodwill and intangible assets recognized.

Corporate Governance

Legal Proceedings

• The BDS Business is involved in an intellectual property licensing agreement dispute where a counterparty asserted that the BDS Business has underpaid royalties.
• The BDS Business is subject to Italy legislation requiring medical technology companies to make payments if medical device expenditures exceed annual regional expenditure ceilings, with an accrual of $17 million recorded in fiscal year 2024.

Related Party Transactions

• BD will continue to provide certain products and services to Waters under a Transition Services Agreement.
• BD will manufacture certain products for the BDS Business and its subsidiaries under contract manufacturing agreements following the Distribution.
• BD will operate the assets and liabilities of the Deferred Close Businesses on Waters' behalf and at the sole direction of Waters under an Interim Operating Agreement, with Waters receiving net profits or reimbursing net losses.

Stakeholder Impact

• Shareholders of Waters will experience significant dilution, with former BD shareholders owning approximately 39.2% of the combined company, and a substantial decrease in pro forma EPS.
• Former BD shareholders received Waters Common Stock, becoming new shareholders in the combined entity.
• Employees of the BDS Business had their BD stock appreciation rights and restricted stock units converted into Waters stock appreciation rights and restricted stock unit awards.
• Customers of the BDS Business were informed that Waters completed the acquisition and is now responsible for providing the product or service.
• Creditors of SpinCo will have Waters Corporation as a guarantor for the $4.0 billion debt incurred by SpinCo.

Next Steps

• Waters expects to file a registration statement on Form S-3 promptly after this Current Report on Form 8-K.
• The SpinCo Financing is expected to be replaced by Permanent SpinCo Financing, potentially through the issuance of senior unsecured notes.
• Waters and BD will work to transfer the Deferred Close Businesses as promptly as reasonably practicable.
• Waters management will perform a detailed review of the BDS Business's accounting policies to identify potential differences.
• Final valuations for purchase price allocation will be completed no later than one year after the consummation of the Merger.

Key Dates

Recommendation

The acquisition of the BDS Business by Waters is a transformative event, creating a larger entity with diversified offerings in life sciences and diagnostics. While the transaction is structured for tax efficiency and includes growth platforms, the immediate financial impact is a significant reduction in pro forma net income and EPS for the combined entity, largely due to the substantial debt incurred and the recent revenue declines in the acquired business. The preliminary nature of valuations, ongoing integration challenges, and delays in transferring certain assets introduce considerable uncertainty. A 'hold' recommendation is prudent as investors await clearer signs of successful integration, debt refinancing, and a turnaround in the BDS Business's performance to assess the long-term value creation potential.

Keywords

Waters Corporation, Becton Dickinson, BD, Biosciences, Diagnostic Solutions, Merger, Acquisition, Spin-off, Reverse Morris Trust, Pro Forma Financials, SEC Filing, Life Sciences, Diagnostics, Financial Reporting, Corporate Governance, Debt Financing